Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingLong non-coding RNAs in anti-cancer drug resistanceInhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationA Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerNilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growthIdentification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells.UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.Potential mechanisms of resistance to venetoclax and strategies to circumvent it.Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.Chronic myeloid leukemia: Second-line drugs of choice.An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer.MicroRNA-mediated drug resistance in ovarian cancer.VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells.Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cellsMode of Action Analyses of Neferine, a Bisbenzylisoquinoline Alkaloid of Lotus (Nelumbo nucifera) against Multidrug-Resistant Tumor Cells.Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration.The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions.Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Synthesis of sericin-based conjugates by click chemistry: enhancement of sunitinib bioavailability and cell membrane permeation.Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.
P2860
Q23923997-396DDD2F-8D46-4BF0-AAE7-FA72865A486DQ28072366-CD439168-3EF4-4794-9A3C-BECD1B196065Q28079309-3DDB00F2-B7E9-4875-9481-1E289C1D845DQ28551341-6771E88A-E838-4279-AF96-55D680ED4DD9Q31142213-E3B41EC8-4C95-409B-A4CC-51F102729496Q33588245-89A18DA5-6061-42E1-95B1-103A740885F2Q35968059-4744DD7C-CB40-4E37-A558-29FF4A0CBFBBQ36088545-75DF30C2-8B1D-4404-B240-1B0D4203EB39Q36392035-9DF8609A-3E5B-4B22-96EE-146D4EA38CE9Q38604104-6A157564-B1EA-4BEC-80F8-9C481A1EF989Q38640422-409E2765-C62A-48BA-A298-0139C572A5CCQ38672008-126D8BD6-233A-4B86-BBA2-DA8589EB06F9Q38778888-4E0BBF24-3854-4161-963E-5F5153CA653DQ38839367-CE670B5A-B288-46AD-B0D3-CAB4CC0E5EFDQ38909416-52DBF39F-54F4-4989-8244-9B81CAD8B293Q38948507-6DCCF385-2A59-4E72-B3E7-75237061CC83Q38960724-82E09B6F-4666-4CF9-AFB0-E820EC9B19D9Q39382756-4F35497E-80D3-4D7D-A446-E4DCD56FA26DQ39787455-4737455E-3D3E-4F52-9E2B-E4B2C29E378DQ42223215-3B05844C-E0D2-4982-B1F0-23D4A5E8385AQ42240230-C0D3F3D0-91D0-468C-B8F6-EA28D446FF91Q42672393-AFE25DF2-5101-43D9-984A-49B34790D358Q42947134-0571DE06-4B09-4FE8-B866-BA99F8F57A7CQ47575091-D2924387-64AA-4217-8BAE-71528CFB32B8Q48154526-41F84DAF-0E5D-4BA7-B92A-D541BC34BC6AQ50997822-6D60E7E4-1D0B-4683-B391-4B5EB1E8BF2CQ51144290-DA1463C7-5A37-4452-8602-02098A7D579BQ54109036-19D5662D-AF51-4874-8311-60BE087E8A0BQ54119186-99844EDF-FC24-4F13-9AB1-44D7458A6FEF
P2860
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Use of second- and third-gener ...... n evolving treatment paradigm.
@en
type
label
Use of second- and third-gener ...... n evolving treatment paradigm.
@en
prefLabel
Use of second- and third-gener ...... n evolving treatment paradigm.
@en
P2860
P50
P1476
Use of second- and third-gener ...... n evolving treatment paradigm.
@en
P2860
P304
P356
10.1016/J.CLML.2015.03.006
P407
P577
2015-03-24T00:00:00Z